1. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT
- Author
-
Gwendolyn Van Gorkom, Patrice Chevallier, Nicolaus Kröger, Fabio Ciceri, Carol Moreno, Johannes Schetelig, Henric-Jan Blok, Paolo Corradini, Roberto Foa, Yener Koc, M. T. Van Lint, Dietrich W. Beelen, Didier Blaise, Johanna Tischer, Dominik Selleslag, Lutz P. Müller, Inken Hilgendorf, Joerg Thomas Bittenbring, Matthias Theobald, Dirk-Jan Eikema, Michel van Gelder, Michael Hallek, Carlos Solano, Luca Castagna, van Gorkom, Gwendolyn, van Gelder, Michel, Eikema, Dirk-Jan, Blok, Henric-Jan, van Lint, M. T., Koc, Yener, Ciceri, Fabio, Beelen, Dietrich, Chevallier, Patrice, Selleslag, Dominik, Blaise, Didier, Foá, Roberto, Corradini, Paolo, Castagna, Luca, Moreno, Carol, Solano, Carlo, Müller, Lutz Peter, Tischer, Johanna, Hilgendorf, Inken, Hallek, Michael, Bittenbring, Jörg, Theobald, Matthia, Schetelig, Johanne, Kröger, Nicolaus, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Promovendi ODB, Interne Geneeskunde, and MUMC+: MA Hematologie (9)
- Subjects
Oncology ,Male ,BLOOD ,Chronic lymphocytic leukemia ,medicine.medical_treatment ,Medizin ,MULTICENTER ,Graft vs Host Disease ,Hematopoietic stem cell transplantation ,0302 clinical medicine ,immune system diseases ,hemic and lymphatic diseases ,Medicine ,POSTTRANSPLANTATION CYCLOPHOSPHAMIDE ,Cumulative incidence ,ALLOGENEIC TRANSPLANTATION ,DONOR TRANSPLANTATION ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,EUROPEAN-SOCIETY ,surgical procedures, operative ,Treatment Outcome ,Transplantation ,030220 oncology & carcinogenesis ,SURVIVAL ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,Allogeneic transplantation ,Cyclophosphamide ,MINIMAL RESIDUAL DISEASE ,03 medical and health sciences ,Internal medicine ,Humans ,Aged ,Retrospective Studies ,business.industry ,Retrospective cohort study ,medicine.disease ,Minimal residual disease ,BONE-MARROW-TRANSPLANTATION ,Leukemia, Lymphocytic, Chronic, B-Cell ,Survival Analysis ,Transplantation, Haploidentical ,business ,CLL ,030215 immunology - Abstract
Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.
- Published
- 2017